- Home
- LXEH vs XRTX Comparison
LXEH vs XRTX Comparison
Compare LXEH & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- XRTX
- Stock Information
- Founded
- LXEH 2001
- XRTX 2011
- Country
- LXEH China
- XRTX Canada
- Employees
- LXEH N/A
- XRTX N/A
- Industry
- LXEH Other Consumer Services
- XRTX Pharmaceuticals and Biotechnology
- Sector
- LXEH Real Estate
- XRTX Health Care
- Exchange
- LXEH Nasdaq
- XRTX Nasdaq
- Market Cap
- LXEH 4.7M
- XRTX 4.1M
- IPO Year
- LXEH 2020
- XRTX N/A
- Fundamental
- Price
- LXEH $3.55
- XRTX $1.15
- Analyst Decision
- LXEH
- XRTX Strong Buy
- Analyst Count
- LXEH 0
- XRTX 1
- Target Price
- LXEH N/A
- XRTX $14.00
- AVG Volume (30 Days)
- LXEH 8.0K
- XRTX 16.7K
- Earning Date
- LXEH 09-27-2024
- XRTX 11-15-2024
- Dividend Yield
- LXEH N/A
- XRTX N/A
- EPS Growth
- LXEH N/A
- XRTX N/A
- EPS
- LXEH N/A
- XRTX N/A
- Revenue
- LXEH $5,628,870.00
- XRTX N/A
- Revenue This Year
- LXEH N/A
- XRTX N/A
- Revenue Next Year
- LXEH N/A
- XRTX N/A
- P/E Ratio
- LXEH N/A
- XRTX N/A
- Revenue Growth
- LXEH N/A
- XRTX N/A
- 52 Week Low
- LXEH $1.95
- XRTX $1.09
- 52 Week High
- LXEH $65.06
- XRTX $7.00
- Technical
- Relative Strength Index (RSI)
- LXEH 51.13
- XRTX 40.84
- Support Level
- LXEH $2.26
- XRTX $1.14
- Resistance Level
- LXEH $2.47
- XRTX $1.25
- Average True Range (ATR)
- LXEH 0.13
- XRTX 0.09
- MACD
- LXEH 0.03
- XRTX 0.01
- Stochastic Oscillator
- LXEH 50.10
- XRTX 10.71
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.